149 related articles for article (PubMed ID: 29417827)
1. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.
Flanders SC; Kim J; Wilson S; Braziunas J; Greenfield S; Billimek J; Lechpammer S; Lin DW; Karsh L; Quinn DI; Shevrin D; Shore ND; Symanowski JT; Penson DF
Future Oncol; 2018 Mar; 14(6):527-536. PubMed ID: 29417827
[TBL] [Abstract][Full Text] [Related]
2. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice.
Litwin MS; Greenfield S; Elkin EP; Lubeck DP; Broering JM; Kaplan SH
Cancer; 2007 May; 109(9):1777-83. PubMed ID: 17354226
[TBL] [Abstract][Full Text] [Related]
3. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer.
Stier DM; Greenfield S; Lubeck DP; Dukes KA; Flanders SC; Henning JM; Weir J; Kaplan SH
Urology; 1999 Sep; 54(3):424-9. PubMed ID: 10475347
[TBL] [Abstract][Full Text] [Related]
4. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research.
Penson DF; Lin DW; Karsh L; Quinn DI; Shevrin DH; Shore N; Symanowski JT; Brown B; Forer D; Wong EK; Flanders SC
Future Oncol; 2016 Dec; 12(23):2689-2699. PubMed ID: 27528114
[TBL] [Abstract][Full Text] [Related]
5. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
Fallara G; Gedeborg R; Bill-Axelson A; Garmo H; Stattin P
PLoS One; 2021; 16(7):e0255239. PubMed ID: 34320037
[TBL] [Abstract][Full Text] [Related]
6. From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer.
Daskivich TJ; van de Poll-Franse LV; Kwan L; Sadetsky N; Stein DM; Litwin MS
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):320-7. PubMed ID: 20838413
[TBL] [Abstract][Full Text] [Related]
7. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
9. Consideration of comorbidity in risk stratification prior to prostate biopsy.
Liss MA; Billimek J; Osann K; Cho J; Moskowitz R; Kaplan A; Szabo RJ; Kaplan SH; Greenfield S; Dash A
Cancer; 2013 Jul; 119(13):2413-8. PubMed ID: 23619920
[TBL] [Abstract][Full Text] [Related]
10. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
Svensson J; Lissbrant IF; Gauffin O; Hjälm-Eriksson M; Kilany S; Fagerlund K; Stattin P
Scand J Urol; 2021 Feb; 55(1):1-8. PubMed ID: 33300403
[TBL] [Abstract][Full Text] [Related]
11. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
[TBL] [Abstract][Full Text] [Related]
12. Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Westgeest HM; Uyl-de Groot CA; van Moorselaar RJA; de Wit R; van den Bergh ACM; Coenen JLLM; Beerlage HP; Hendriks MP; Bos MMEM; van den Berg P; van de Wouw AJ; Spermon R; Boerma MO; Geenen MM; Tick LW; Polee MB; Bloemendal HJ; Cordia I; Peters FPJ; de Vos AI; van den Bosch J; van den Eertwegh AJM; Gerritsen WR
Eur Urol Focus; 2018 Sep; 4(5):694-701. PubMed ID: 28753794
[TBL] [Abstract][Full Text] [Related]
13. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries.
Vassilev ZP; Gabarró MS; Kaye JA; Saltus CW; Riedel O; Scholle O; Mehtälä J; Korhonen P; Garbe E; Zong J
Future Oncol; 2020 Sep; 16(25):1889-1901. PubMed ID: 32515225
[No Abstract] [Full Text] [Related]
14. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.
Sternberg CN; Baskin-Bey ES; Watson M; Worsfold A; Rider A; Tombal B
BMC Urol; 2013 Nov; 13():58. PubMed ID: 24206580
[TBL] [Abstract][Full Text] [Related]
15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
18. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
19. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N
Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590
[TBL] [Abstract][Full Text] [Related]
20. Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment.
Mansinho A; Macedo D; Fernandes I; Costa L
Adv Exp Med Biol; 2018; 1096():117-133. PubMed ID: 30324351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
